Claritev Q1 Revenue $244.7M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Should l Buy CTEV?
Reports Q1 revenue $244.7M, consensus $238.59M. "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence - confidence in our team, confidence in our growth, and confidence in the durability of the foundation we are building," said Travis Dalton, CEO. "..our Q1 performance underscores how the combination of that vision and our competitive position is leading to greater success and faster growth. We will continue to press that competitive advantage - one that is grounded in our long-standing trusted client relationships, scaled data ecosystem, deep domain expertise, and increasingly, our differentiated application of AI to accelerate progress." CFO Doug Garis commented, "Our Q1 results demonstrate the consistency and quality of Claritev's core, and the growth opportunities created by our expansion into new markets and verticals...Notably, the strong Q1 bookings performance comes from our core offerings and markets, alongside significant wins in the provider and government verticals, demonstrating the diversification of Claritev's revenue streams and the foundation we are building to deliver sustainable, long term growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTEV
Wall Street analysts forecast CTEV stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 26.470
Low
33.00
Averages
62.00
High
90.00
Current: 26.470
Low
33.00
Averages
62.00
High
90.00
About CTEV
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Claritev Corporation Q1 2026 Earnings Call Insights
- Strong Contract Value: Claritev secured over $40 million in annual contract value bookings in Q1 2026, supporting its sales target of $80 million to $100 million for the year, indicating robust demand and growth potential in the market.
- Revenue and EBITDA Growth: The company reported total revenue of $244.7 million for the quarter, a 5.8% year-over-year increase, while adjusted EBITDA reached $146.9 million, up 3.4%, demonstrating ongoing improvements in profitability and operational efficiency.
- Cash Flow Performance: Despite generating $36.8 million in unlevered free cash flow, the company utilized $92.5 million in free cash flow, with management expecting Q1 and Q3 to be cash consumption quarters, while Q2 and Q4 are anticipated to be cash-generating, reflecting seasonal cash flow challenges.
- Market Expansion and New Clients: The agreement with GDIT to provide a custom network for the World Trade Center Health Program signifies entry into a new public sector market, further enhancing its strategic position in diversified business operations.
See More
Claritev Reports Q1 2026 Financial Results with Mixed Performance
- Financial Performance: Claritev's Q1 2026 GAAP EPS of -$4.41 missed expectations by $0.34, indicating ongoing profitability challenges, while revenue of $244.7 million beat estimates by $6.11 million, suggesting positive revenue growth amidst difficulties.
- Net Loss Analysis: The net loss of $73.6 million for Q1 2026 increased from $71.3 million in Q1 2025, reflecting challenges in cost control and profitability that could impact investor confidence moving forward.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 2026 was $146.9 million, a 3.4% increase year-over-year, indicating improvements in operational efficiency, although the overall financial performance remains concerning.
- Cash Flow Situation: Net cash used in operating activities reached $45.8 million in Q1 2026, up from $30.1 million in Q1 2025, with free cash flow at -$92.5 million, highlighting pressures in cash flow management that may affect future investment capabilities.
See More
Claritev Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement: Claritev is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimated at $1.38 and revenue projected at $238.59 million, providing crucial financial health indicators for investors.
- Revenue Guidance: The company outlines a revenue target of $980 million to $1 billion by 2026, indicating strong growth potential amid accelerating digital transformation, which may attract increased investor interest in its long-term prospects.
- Rating Upgrade: Claritev's combination of compounding debt and stabilization of its legacy business has led analysts to upgrade its rating, reflecting market confidence in its improving financial condition, which could positively impact its stock price.
- Market Dynamics: As Claritev approaches its earnings release, companies like Amerigo and Allianz are viewed as strong buys, while Ashford Hospitality and Hudson Pacific lag, highlighting varying investor confidence across different firms.
See More
Claritev Achieves Significant Progress in Healthcare AI
- Leadership Recognition: Claritev's Chief AI Officer, Fernando Schwartz, has been named to the 2026 DataIQ 100 North America list, highlighting the company's impactful application of data and AI in healthcare, thereby enhancing its industry reputation.
- AI Integration in Workflows: Schwartz focuses on operationalizing AI to improve coding accuracy and identify performance patterns, enabling healthcare organizations to gain actionable insights at scale, which significantly enhances financial performance.
- Accelerated Digital Transformation: Michael Kim, Claritev's Chief Digital Officer, notes that Schwartz's leadership is accelerating the company's digital transformation, ensuring that AI technologies are embedded directly into the most critical workflows to improve overall operational efficiency.
- Strategic Vision: President Travis Dalton emphasizes that AI is a critical driver of Claritev's strategy, aiming to leverage advanced analytics and AI to deliver measurable impacts for clients and the broader healthcare system, promoting transparency and affordability in healthcare.
See More
Claritev Launches Rural Health Grant Program
- Foundation Launch: Claritev Corporation has established the Claritev Cares™ charitable foundation, aimed at expanding healthcare access through its Rural Health Grant program, with applications open until June 1, 2026, expected to support over 100 rural health initiatives.
- Significant Historical Contributions: Since 1995, Claritev has donated over $700,000 to underserved communities, supporting the expansion of essential services in hospitals and rural health clinics, demonstrating the company's long-term commitment to community health.
- Far-reaching Funding Impact: The 2024 Rural Health Grant recipient, New River Health Association, reported that the funding allowed them to increase patient care visits and introduce additional diagnostic services, significantly enhancing the quality of healthcare in their community.
- Global Influence Expansion: Claritev Cares also made a $10,000 donation to World Central Kitchen, reflecting the company's commitment to supporting communities globally, thereby enhancing its strategic impact on healthcare accessibility.
See More
Middle East Conflict Heightens Market Uncertainty
- Escalating Market Risks: The closure of the Strait of Hormuz disrupts approximately 20% of global oil and LNG flows, tightening insurance markets and prompting panic selling among investors, thereby exacerbating overall economic uncertainty.
- Insider Buying Signals: Prior to the escalation of conflict, insiders at companies like CoStar Group, Hamilton Lane, Vornado Realty Trust, and Claritev Corporation made significant purchases, indicating their confidence in the long-term prospects of these firms, especially during turbulent market conditions.
- Real Estate Market Recovery Expectations: Despite a brutal reset in the commercial real estate market, insider buying at CoStar Group suggests confidence in the normalization of future transaction activity, potentially driving a rebound in this sector.
- Stability in Healthcare Technology: Insider purchases at Claritev Corporation before the conflict indicate that, despite heightened geopolitical risks, demand in the healthcare technology sector remains robust, expected to sustain stable cash flows and market positioning.
See More
Claritev Corporation Q1 2026 Earnings Call Insights
- Strong Contract Value: Claritev secured over $40 million in annual contract value bookings in Q1 2026, supporting its sales target of $80 million to $100 million for the year, indicating robust demand and growth potential in the market.
- Revenue and EBITDA Growth: The company reported total revenue of $244.7 million for the quarter, a 5.8% year-over-year increase, while adjusted EBITDA reached $146.9 million, up 3.4%, demonstrating ongoing improvements in profitability and operational efficiency.
- Cash Flow Performance: Despite generating $36.8 million in unlevered free cash flow, the company utilized $92.5 million in free cash flow, with management expecting Q1 and Q3 to be cash consumption quarters, while Q2 and Q4 are anticipated to be cash-generating, reflecting seasonal cash flow challenges.
- Market Expansion and New Clients: The agreement with GDIT to provide a custom network for the World Trade Center Health Program signifies entry into a new public sector market, further enhancing its strategic position in diversified business operations.
See More
Claritev Reports Q1 2026 Financial Results with Mixed Performance
- Financial Performance: Claritev's Q1 2026 GAAP EPS of -$4.41 missed expectations by $0.34, indicating ongoing profitability challenges, while revenue of $244.7 million beat estimates by $6.11 million, suggesting positive revenue growth amidst difficulties.
- Net Loss Analysis: The net loss of $73.6 million for Q1 2026 increased from $71.3 million in Q1 2025, reflecting challenges in cost control and profitability that could impact investor confidence moving forward.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 2026 was $146.9 million, a 3.4% increase year-over-year, indicating improvements in operational efficiency, although the overall financial performance remains concerning.
- Cash Flow Situation: Net cash used in operating activities reached $45.8 million in Q1 2026, up from $30.1 million in Q1 2025, with free cash flow at -$92.5 million, highlighting pressures in cash flow management that may affect future investment capabilities.
See More
Claritev Scheduled to Announce Q1 Earnings on May 7
- Earnings Announcement: Claritev is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimated at $1.38 and revenue projected at $238.59 million, providing crucial financial health indicators for investors.
- Revenue Guidance: The company outlines a revenue target of $980 million to $1 billion by 2026, indicating strong growth potential amid accelerating digital transformation, which may attract increased investor interest in its long-term prospects.
- Rating Upgrade: Claritev's combination of compounding debt and stabilization of its legacy business has led analysts to upgrade its rating, reflecting market confidence in its improving financial condition, which could positively impact its stock price.
- Market Dynamics: As Claritev approaches its earnings release, companies like Amerigo and Allianz are viewed as strong buys, while Ashford Hospitality and Hudson Pacific lag, highlighting varying investor confidence across different firms.
See More
Claritev Achieves Significant Progress in Healthcare AI
- Leadership Recognition: Claritev's Chief AI Officer, Fernando Schwartz, has been named to the 2026 DataIQ 100 North America list, highlighting the company's impactful application of data and AI in healthcare, thereby enhancing its industry reputation.
- AI Integration in Workflows: Schwartz focuses on operationalizing AI to improve coding accuracy and identify performance patterns, enabling healthcare organizations to gain actionable insights at scale, which significantly enhances financial performance.
- Accelerated Digital Transformation: Michael Kim, Claritev's Chief Digital Officer, notes that Schwartz's leadership is accelerating the company's digital transformation, ensuring that AI technologies are embedded directly into the most critical workflows to improve overall operational efficiency.
- Strategic Vision: President Travis Dalton emphasizes that AI is a critical driver of Claritev's strategy, aiming to leverage advanced analytics and AI to deliver measurable impacts for clients and the broader healthcare system, promoting transparency and affordability in healthcare.
See More
Claritev Launches Rural Health Grant Program
- Foundation Launch: Claritev Corporation has established the Claritev Cares™ charitable foundation, aimed at expanding healthcare access through its Rural Health Grant program, with applications open until June 1, 2026, expected to support over 100 rural health initiatives.
- Significant Historical Contributions: Since 1995, Claritev has donated over $700,000 to underserved communities, supporting the expansion of essential services in hospitals and rural health clinics, demonstrating the company's long-term commitment to community health.
- Far-reaching Funding Impact: The 2024 Rural Health Grant recipient, New River Health Association, reported that the funding allowed them to increase patient care visits and introduce additional diagnostic services, significantly enhancing the quality of healthcare in their community.
- Global Influence Expansion: Claritev Cares also made a $10,000 donation to World Central Kitchen, reflecting the company's commitment to supporting communities globally, thereby enhancing its strategic impact on healthcare accessibility.
See More
Middle East Conflict Heightens Market Uncertainty
- Escalating Market Risks: The closure of the Strait of Hormuz disrupts approximately 20% of global oil and LNG flows, tightening insurance markets and prompting panic selling among investors, thereby exacerbating overall economic uncertainty.
- Insider Buying Signals: Prior to the escalation of conflict, insiders at companies like CoStar Group, Hamilton Lane, Vornado Realty Trust, and Claritev Corporation made significant purchases, indicating their confidence in the long-term prospects of these firms, especially during turbulent market conditions.
- Real Estate Market Recovery Expectations: Despite a brutal reset in the commercial real estate market, insider buying at CoStar Group suggests confidence in the normalization of future transaction activity, potentially driving a rebound in this sector.
- Stability in Healthcare Technology: Insider purchases at Claritev Corporation before the conflict indicate that, despite heightened geopolitical risks, demand in the healthcare technology sector remains robust, expected to sustain stable cash flows and market positioning.
See More
